Is Arcus Biosciences, Inc. (RCUS) a Buy, Sell, or Hold?
NYSE : RCUS
Arcus Biosciences, Inc. — Institutional Ownership
$27.88 USD
$1.43 (5.41%)
- Volume
- 224.15K
- Average Volume
- 1.23M
- Market Capitalization
- $3.51B
- P/E Ratio
- -8.80
- Dividend Yield
- 0.00%
- Price Target
- $35.00
- Year High
- $31.74
- Year Low
- $8.84
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.04
Institutional Ownership Summary
Institutional Ownership %
0.40%
Investors Holding
33
change: -188 | last: 221
Increased Positions
16
change: -104 | last: 120
Reduced Positions
6
change: -49 | last: 55
New Positions
6
change: -31 | last: 37
Sold Positions
182
change: 144 | last: 38
Total Calls
-
Total Puts
-
Put-Call Ratio
0.00
change: -46.1185 | last: 0.4612
Total Invested
15.44M
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-03-26 | The Vanguard Group | - | 0.00% |
| 2026-01-08 | BlackRock, Inc. | 12.74M | 10.40% |
| 2025-11-14 | Point72 Asset Management, L.P. | 4.33M | 4.10% |
| 2025-11-05 | GILEAD SCIENCES, INC. | 31.42M | 25.60% |
| 2025-07-15 | GILEAD SCIENCES, INC. | 31.42M | 29.70% |
| 2025-05-13 | Point72 Asset Management, L.P. | 5.83M | 5.50% |
| 2025-04-17 | BlackRock, Inc. | 9.98M | 9.40% |
| 2025-03-05 | GILEAD SCIENCES, INC. | 39.69M | 35.00% |
| 2025-02-20 | GILEAD SCIENCES, INC. | 39.69M | 35.00% |
| 2024-11-08 | (1) BlackRock, Inc. | 9.73M | 10.60% |
| 2024-02-09 | Abigail P. Johnson | 4.73M | 6.32% |
| 2024-02-09 | FMR LLC | 4.73M | 6.32% |
| 2024-01-24 | STATE STREET CORPORATION | 4.24M | 5.66% |
| 2023-02-09 | The Vanguard Group - 23-1945930 | 4.37M | 6.04% |
| 2022-10-17 | 2. | 10.0 | 5.50% |
| 2022-10-17 | 2. | 10.0 | 5.50% |
| 2022-10-17 | 2. | 10.0 | 5.50% |
| 2022-10-17 | 2. | 10.0 | 5.50% |
| 2022-05-09 | (1)Names of reporting persons. BlackRock, Inc. | 7.97M | 11.10% |
| 2022-03-14 | Biotechnology Value Trading Fund OS LP | 194.51K | 1.00% |
| 2022-03-14 | Biotechnology Value Fund II, L.P. | 1.54M | 2.20% |
| 2022-03-14 | Biotechnology Value Fund, L.P. | 2.16M | 3.00% |
| 2022-03-14 | BVF Partners L.P. | 3.96M | 5.60% |
| 2022-03-14 | Mark N. Lampert | 3.96M | 5.60% |
| 2022-03-14 | BVF Inc. | 3.96M | 5.60% |
| 2022-03-14 | BVF GP Holdings LLC | 3.7M | 5.20% |
| 2022-03-14 | BVF Partners OS Ltd. | 194.51K | 1.00% |
| 2022-03-14 | BVF I GP LLC | 2.16M | 3.00% |
| 2022-03-14 | BVF II GP LLC | 1.54M | 2.20% |
| 2022-02-14 | GV 2016, L.P. | 638.97K | 0.91% |
| 2022-02-04 | (1) BlackRock, Inc. | 4.13M | 5.90% |
| 2021-07-19 | EcoR1 Capital, LLC | 4.57M | 11.00% |
| 2021-07-19 | Oleg Nodelman | 4.57M | 11.00% |
| 2021-07-19 | EcoR1 Capital Fund Qualified, L.P. | 3.99M | 11.00% |
| 2021-03-10 | (1) BlackRock, Inc. | 3.37M | 4.80% |
| 2021-02-16 | Boxer Capital, LLC | 2.08M | 3.20% |
| 2021-02-02 | (1) BlackRock, Inc. | 3.26M | 5.00% |
| 2020-11-09 | PFM Health Sciences, LP | 6.0 | 5.20% |
| 2020-10-15 | Anita Galeana | 1.57M | 2.42% |
| 2020-10-15 | Juan Jaen, Ph.D. | 1.89M | 2.92% |
| 2020-10-15 | Juan Carlos Jaen and Anita Galeana 2000 Trust | 1.57M | 2.42% |
| 2020-07-17 | Gilead Sciences, Inc. | 29.5M | 35.00% |
| 2020-03-05 | Juan Jaen, Ph.D. | 3.04M | 6.62% |
| 2020-03-05 | Terry Rosen, Ph.D. | 4.29M | 9.34% |
| 2020-03-05 | Victoria Rosen | 4.02M | 8.77% |
| 2020-03-05 | Anita Galeana | 2.78M | 6.06% |
| 2020-03-05 | Juan Carlos Jaen and Anita Galeana 2000 Trust | 2.78M | 6.06% |
| 2020-03-05 | The Rosen 1996 Family Trust | 3.02M | 6.59% |
| 2020-02-13 | Boxer Asset Management Inc. | 3.02M | 6.60% |
| 2020-02-13 | Boxer Capital, LLC | 3.02M | 6.60% |
| 2020-02-13 | Joe Lewis | 3.02M | 6.60% |
| 2020-02-07 | (1) BlackRock, Inc. | 3.01M | 6.60% |
| 2019-02-12 | Wellington Management Company LLP | 4.08M | 9.18% |
| 2019-02-12 | Wellington Management Group LLP | 4.28M | 9.64% |
| 2019-02-12 | Wellington Group Holdings LLP | 4.28M | 9.64% |
| 2019-02-12 | Wellington Investment Advisors Holdings LLP | 4.28M | 9.64% |
| 2019-02-12 | 13G | 5.05M | 11.36% |
| 2019-02-12 | 13G | 5.05M | 11.36% |
| 2019-02-12 | 13G | 1.92M | 4.33% |
| 2019-02-12 | 13G | 1.92M | 4.33% |
| 2019-02-12 | 13G | 3.13M | 7.03% |
| 2019-02-12 | 13G | 3.13M | 7.03% |
| 2019-02-12 | 13G | 3.13M | 7.03% |
| 2019-02-12 | 13G | 5.05M | 11.36% |
| 2019-02-12 | 13G | 1.92M | 4.33% |
| 2018-11-26 | Biotechnology Value Fund, L.P. | 1.19M | 2.70% |
| 2018-11-26 | BVF Partners L.P. | 2.42M | 5.40% |
| 2018-11-26 | BVF Inc. | 2.42M | 5.40% |
| 2018-11-26 | Biotechnology Value Fund II, L.P. | 858.38K | 1.90% |
| 2018-11-26 | Mark N. Lampert | 2.42M | 5.40% |
| 2018-11-26 | BVF Partners OS Ltd. | 185.8K | 1.00% |
| 2018-11-26 | Biotechnology Value Trading Fund OS LP | 185.8K | 1.00% |
| 2018-03-23 | James Tananbaum (“Tananbaum”) | 4.1M | 9.60% |
| 2018-03-23 | Foresite Capital Fund III, L.P. (“FCF III”) | 3.45M | 8.10% |
| 2018-03-23 | Foresite Capital Management IV, LLC (“FCM IV”) | 650K | 1.50% |
| 2018-03-23 | Foresite Capital Fund IV, L.P. (“FCF IV”) | 650K | 1.50% |
| 2018-03-23 | Foresite Capital Management III, LLC (“FCM III”) | 3.45M | 8.10% |
RCUS Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $23.83 | 107.4M | $2.56B | $222M | $112M | $2.45B |
| 2024-12-31 | $14.89 | 90.1M | $1.34B | $150M | $60M | $1.25B |
| 2023-12-31 | $19.10 | 74M | $1.41B | $127M | $11M | $1.3B |
| 2022-12-31 | $20.68 | 72M | $1.49B | $206M | $120M | $1.4B |
| 2021-12-31 | $40.47 | 69.35M | $2.81B | $147.91M | $121.99M | $2.78B |
| 2020-12-31 | $25.96 | 54.79M | $1.42B | $173.42M | $18.11M | $1.27B |
| 2019-12-31 | $10.10 | 43.83M | $442.64M | $57.94M | -$ | $384.71M |
| 2018-12-31 | $10.77 | 34.62M | $372.84M | $71.06M | -$ | $301.77M |
| 2017-12-31 | $17.00 | 24.55M | $417.43M | $98.43M | -$ | $319M |
| 2016-12-31 | $17.00 | 24.55M | $417.43M | $65.16M | -$ | $352.27M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $21.60 | 125.4M | $2.71B | $201M | $113M | $2.62B |
| 2025-12-31 | $23.83 | 107.4M | $2.56B | $222M | $112M | $2.45B |
| 2025-09-30 | $13.60 | 106.5M | $1.45B | $238M | $111M | $1.32B |
| 2025-06-30 | $8.14 | 106.1M | $863.65M | $248M | $109M | $724.65M |
| 2025-03-31 | $7.85 | 98.4M | $772.44M | $192M | $60M | $640.44M |
| 2024-12-31 | $14.89 | 91.7M | $1.37B | $150M | $60M | $1.28B |
| 2024-09-30 | $15.29 | 91.4M | $1.4B | $201M | $58M | $1.25B |
| 2024-06-30 | $15.30 | 91.1M | $1.39B | $156M | $11M | $1.25B |
| 2024-03-31 | $18.48 | 86.2M | $1.59B | $185M | $11M | $1.42B |
| 2023-12-31 | $19.10 | 75M | $1.43B | $127M | $11M | $1.32B |
| 2023-09-30 | $17.95 | 74.6M | $1.34B | $184M | $9M | $1.16B |
| 2023-06-30 | $20.31 | 73.2M | $1.49B | $230M | -$ | $1.26B |